Unique ID issued by UMIN | UMIN000002913 |
---|---|
Receipt number | R000003549 |
Scientific Title | Multicenter study: Effect of combined therapy using balloon-occluded arterial infusion of anticancer agent with concurrent radiation for elderly patients (or renal failure) with locally invasive bladder cancer |
Date of disclosure of the study information | 2009/12/17 |
Last modified on | 2012/02/28 14:06:25 |
Multicenter study: Effect of combined therapy using balloon-occluded arterial infusion of anticancer agent with concurrent radiation for elderly patients (or renal failure) with locally invasive bladder cancer
Effect of BOAI of anticancer agent with concurrent radiation for locally invasive bladder cancer
Multicenter study: Effect of combined therapy using balloon-occluded arterial infusion of anticancer agent with concurrent radiation for elderly patients (or renal failure) with locally invasive bladder cancer
Effect of BOAI of anticancer agent with concurrent radiation for locally invasive bladder cancer
Japan |
Locally invasive bladder cancer
Urology | Radiology |
Malignancy
NO
The comparison of efficacy and safety between BOAI-CDDP/radiation therapy and total cystectomy for elderly patients (or renal failure) with locally invasive bladder cancer.
Safety,Efficacy
Confirmatory
Pragmatic
Not applicable
progression free survival
Over all survival
Quality of life
incidence rate of adverse event
Interventional
Parallel
Non-randomized
Open -no one is blinded
Active
2
Treatment
Device,equipment | Maneuver |
balloon-occluded-arterial-infusion (BOAI) of anticancer agent (cisplatin/gemcitabine), concomitant with radiation
Total cystectomy
75 | years-old | <= |
Not applicable |
Male and Female
(1) Patients were informed of the investigational nature of the study and provided written informed consent before study enrollment.
(2) patients older than 75 years old, or with renal failure
(3) Histological type should be urothelial cancer.
(4) Stage T2 or T3 muscle-invasive bladder cancer without distant metastasis.
(5) Eastern Cooperative Oncology Group (ECOG) performance status 0-2,
(6) absolute neutrophil count (ANC) of 1,500/L, platelets 100,000/L, creatinine 1.0, bilirubin 3 times the institutional upper limit of the normal range, AST 4 times the institutional upper limit of the normal range,
Patients who :
(1) had prior systemic therapy for bladder cancer (radiation or chemotherapy)
(2) has serious complication (including severe DM)
(3) other cancers.
(4) are pregnant or wish to have baby
(5) are unable to receive this treatment for some reason.
220
1st name | |
Middle name | |
Last name | Haruhito Azuma |
Osaka Medical College
Department of Urology
2-7 Daigaku-cho Takatsuki-city Osaka Japan
072-683-1221
1st name | |
Middle name | |
Last name | Haruhito Azuma |
Osaka Medical College
Department of Urology
2-7 Daigaku-cho Takatsuki-city Osaka Japan
072-683-1221
Department of Urology Osaka Medical College
1, A grant form Cancer treatment foundation
2, A grant form Kenzo Suzuki foundation
3, A grant from the OMC Science Frontier Program for the Promotion of Research in Osaka Medical College
Other
Japan
NO
大阪医科大学附属病院 (大阪府)
2009 | Year | 12 | Month | 17 | Day |
Unpublished
Preinitiation
2009 | Year | 12 | Month | 17 | Day |
2011 | Year | 07 | Month | 01 | Day |
2017 | Year | 12 | Month | 01 | Day |
2017 | Year | 12 | Month | 01 | Day |
2017 | Year | 12 | Month | 01 | Day |
2018 | Year | 06 | Month | 01 | Day |
2009 | Year | 12 | Month | 17 | Day |
2012 | Year | 02 | Month | 28 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003549